This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Parkinsonism and Akathisia With Quetiapine: Three Case Reports

Rahul Bharadwaj, MD, and Sandeep Grover, MD

Published: July 31, 2008

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Quetiapine, a dibenzothiazepine derivative producedby altering the structure of the clozapine molecule, has beenshown to have low to moderate affinity for the D1, D2, 5-HT1A,and 5-HT2A receptors and moderate to high affinity for the a1-and a2-adrenergic receptors. Due to this receptor profile, quetiapinehas been claimed to have a low incidence of extrapyramidalside effects. Large controlled trials have also shown thatquetiapine is associated with placebo-level extrapyramidal sideeffects and akathisia in schizophrenia and bipolar disorder.’ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: Neurologic and Neurocognitive , Parkinson Disease

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...